Lumenis partners with Mandy Moore on DED awareness

Article

The actress and singer-songwriter will serves as the brand ambassador for OptiLight, a new dry eye disease treatment.

Lumenis has launched a partnership with actress and singer-songwriter Mandy Moore as the new brand ambassador for OptiLight, the company’s bright solution for dry eyes. She is featured in a new OptiLight campaign, according to a news release.

OptiLight is the first and only light-based therapy for dry eye disease (DED) that uses a patented optimal pulse technology (OPT). It is designed to help improve DED symptoms with a series of quick, gentle, in-office treatments.

Moore’s partnership with Lumenis comes after she experienced signs and symptoms of DED. She said using OptiLight as treatment significantly improved her condition.

“I’m excited to partner with Lumenis and share how OptiLight has made a real impact on my life. For years, I suffered from dry eye disease, but I didn’t know I had it ... it was a constant frustration on the set and at home with my family,” Moore said, in a statement.

After being diagnosed wtih DED, Moore said receiving treatment from OptiLight allowed her to continue normal life.

"Now, I can focus more time on what’s important to me, rather than battling the constant nuisance and discomfort of dry eye disease, and I want to inspire other people to say, ‘I won’t just live with it,’” she said.

Learn more about OptiLight here

See more dry eye coverage

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Mitch Ibach, OD, FAAO, details a presentation he gave with Tanner Ferguson, MD, at the Collaborative Care Symposium 2025.
Mitch Ibach, OD, FAAO, details the importance of identifying the best candidates and practicing comanagement for refractive surgery.
Mark Bullimore, MCOptom, PhD, details the importance of preparing optometric students for myopic patient care in a Collaborative Care Symposium (CCS) 2025 presentation.
Peter Hersh, MD, stated that the key takeaway from a handful of presentations he gave at CCS 2025 is that successfully treating patients with keratoconus is identifying the disease early.
Mitch Ibach, OD, FAAO, details the importance to unveiling the underlying cause of dry eye in a CCS 2025 presentation.
Bridgitte Shen Lee, OD, FAAO, FBCLA, FEAOO, ponders what she would like to see develop as both a researcher and a clinician in the dry eye space.
Bridgitte Shen Lee, OD, FAAO, FBCLA, FEAOO, discussed research that utilized IQVIA longitudinal prescription claims data from September through November 2023, coinciding with Miebo's FDA approval in September.
Dr Julie Poteet reports on patient-reported outcomes using lipid-containing artificial tear
Susana Marcos, PhD, discusses the implications her research presents for the role optical coherence tomography (OCT) could play in presbyopia and myopia accommodation efforts.
Susana Marcos, PhD, outlines a presentation she gave at ARVO 2025 on a unique utilization of optical coherence tomography.
© 2025 MJH Life Sciences

All rights reserved.